AU2022253547A1 - Methods for controlling immune cell activity - Google Patents

Methods for controlling immune cell activity Download PDF

Info

Publication number
AU2022253547A1
AU2022253547A1 AU2022253547A AU2022253547A AU2022253547A1 AU 2022253547 A1 AU2022253547 A1 AU 2022253547A1 AU 2022253547 A AU2022253547 A AU 2022253547A AU 2022253547 A AU2022253547 A AU 2022253547A AU 2022253547 A1 AU2022253547 A1 AU 2022253547A1
Authority
AU
Australia
Prior art keywords
methods
immune cell
cell activity
controlling immune
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022253547A
Other languages
English (en)
Inventor
Julian Alexander Barden
Ziduo LI
Patrick Schlegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosceptre Pty Ltd
Original Assignee
Biosceptre Aust Pty Ltd
Biosceptre Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901030A external-priority patent/AU2021901030A0/en
Application filed by Biosceptre Aust Pty Ltd, Biosceptre Pty Ltd filed Critical Biosceptre Aust Pty Ltd
Publication of AU2022253547A1 publication Critical patent/AU2022253547A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022253547A 2021-04-08 2022-04-08 Methods for controlling immune cell activity Pending AU2022253547A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021901030A AU2021901030A0 (en) 2021-04-08 Methods for controlling immune cell activity
AU2021901030 2021-04-08
PCT/AU2022/050311 WO2022213154A1 (en) 2021-04-08 2022-04-08 Methods for controlling immune cell activity

Publications (1)

Publication Number Publication Date
AU2022253547A1 true AU2022253547A1 (en) 2023-10-05

Family

ID=83544929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022253547A Pending AU2022253547A1 (en) 2021-04-08 2022-04-08 Methods for controlling immune cell activity

Country Status (9)

Country Link
US (1) US20250282844A1 (https=)
EP (1) EP4319793A4 (https=)
JP (1) JP2024513485A (https=)
CN (1) CN117157092A (https=)
AU (1) AU2022253547A1 (https=)
BR (1) BR112023020659A2 (https=)
CA (1) CA3213042A1 (https=)
MX (1) MX2023011807A (https=)
WO (1) WO2022213154A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024232401A1 (en) * 2023-03-08 2025-08-21 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors for binding to dysfunctional p2x 7 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
CN100497386C (zh) * 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
CN102143978B (zh) * 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
US10858415B2 (en) * 2014-01-29 2020-12-08 Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh Peptide mimotopes of claudin 18.2 and uses thereof
SG11201900344YA (en) * 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2019022796A1 (en) * 2017-07-26 2019-01-31 Panoramic Power Ltd. SYSTEM AND METHOD FOR TIME SYNCHRONIZATION OF SELF-POWERED POWER SENSOR
EP4304610A4 (en) * 2021-03-11 2025-03-05 Biosceptre (Aust) Pty Ltd Novel cell therapy system

Also Published As

Publication number Publication date
WO2022213154A1 (en) 2022-10-13
EP4319793A4 (en) 2025-03-19
BR112023020659A2 (pt) 2023-12-05
EP4319793A1 (en) 2024-02-14
CN117157092A (zh) 2023-12-01
US20250282844A1 (en) 2025-09-11
JP2024513485A (ja) 2024-03-25
MX2023011807A (es) 2024-01-05
CA3213042A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
EP4017530A4 (en) IMMUNE CELLS FOR ADOPTIVE CELL THERAPIES
EP3984709A4 (en) ROBOT CONTROL SYSTEM
EP4114471A4 (en) METHODS, COMPOUNDS AND COMPOSITIONS FOR MODIFYING CAR-T CELL ACTIVITY
EP3964560A4 (en) CELL CULTURE SYSTEM
EP3915736A4 (en) ROBOT CONTROL SYSTEM
AU2022205653A9 (en) T cell therapy
EP4180510A4 (en) CELL CULTURE SYSTEM
AU2022253547A1 (en) Methods for controlling immune cell activity
EP4277703A4 (en) METHODS FOR OPTIMIZING CFTR MODULATOR THERAPY
AU2021901030A0 (en) Methods for controlling immune cell activity
EP4069820A4 (en) MICRO DEVICE FOR CELL CULTURES
AU2021396727A9 (en) A cell culture system controller
EP4360724A4 (en) CONTROL DEVICE
EP4138982A4 (en) ACTIVITY SENSOR CONTROLS
EP4208538A4 (en) RESTORING THE IMMUNE SYSTEM THROUGH CELL THERAPY
EP4024540A4 (en) FUEL CELL SYSTEM AND METHOD OF CONTROLLING THE FUEL CELL SYSTEM
HK40100686A (en) Methods for culturing immune cells
HK40104529A (en) Methods for transducing immune cells
HK40089728A (en) Systems for electroporation
HK40066345A (en) Improved stem cell populations for allogeneic therapy
EP4011447A4 (en) METHOD FOR CULTIVATING DERMAL PAPILLA CELLS
HK40106394A (en) Methods for culturing cells
HK40082375A (en) Engineered cells for therapy
HK40088137A (en) Methods for culturing cells
HK40104134A (en) T cell therapy